Septerna, Inc.
SEPNHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and. Valued at $1.72B, SEPN is a small-cap name in its sector. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Market Cap
$1.72B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-18.93
EPS (TTM)
$-0.53
EPS (Fwd)
$-1.94
ROE
-6.3%
ROA
-7.1%
Cash
$372.3M
Total Debt
$22.5M
Free CF
$29.5M
52W Change
141.5%
Annual Financials
Cash vs Debt
Where SEPN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SEPN finished 22.59% above its 150-day moving average ($30.59) and 26.86% above its 200-day moving average ($29.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SEPN overbought or oversold?
At the September 3, 2026 close, SEPN's RSI(14) was 15.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $372.3M in cash and $22.5M in debt, SEPN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $29.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -6.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Septerna, Inc. and its sector.